Levothyroxine Replacement Therapy and Overuse: A Timely Diagnostic Approach
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Levothyroxine (LT4) is one of the most prescribed drugs worldwide. Once started, approximately 90% of patients continue treatment long term. However, accumulating evidence suggests that many patients, for whom the indication for its administration is not adequately established and the diagnosis is not well documented, are overusing it. This study aimed to evaluate the necessity for and determine potential prognostic factors of long-term LT4 supplementation. METHODS: A prospective clinical cohort follow-up study was carried out. In 291 subjects (84% females) aged 48 ± 16 years on LT4 replacement therapy without a solid diagnosis of hypothyroidism being provided, the treatment was paused. At the beginning and after six to eight weeks of treatment discontinuation, thyrotropin (TSH) and free thyroxine levels were assessed, and thyroid ultrasound was performed. A TSH value of ≥4.5 IU/mL was considered as underlying hypothyroidism. RESULTS: Among the 291 individuals, 114 became hypothyroid (group A), while 177 subjects remained euthyroid off LT4 (group B; 39.2% vs. 60.8%, p < 0.001). The groups were comparable regarding sex, family history, age, body mass index, duration of treatment, basal TSH and free thyroxine values, thyroid volume, and presence of thyroid autoantibodies. However, diffuse inhomogeneous echogenicity on ultrasound examination was significantly higher (p < 0.001) in group A. CONCLUSIONS: These findings suggest considerable overuse of thyroxine therapy. The results underline the initial need to establish the diagnosis firmly before treatment initiation and to undertake periodic evaluation of all patients on chronic LT4 treatment as to the necessity for treatment continuation. In all patients on long-term LT4 therapy in whom the diagnosis has not been definitively established, it appears rational to introduce a six- to eight-week period of LT4 replacement therapy discontinuation, preceded and followed by TSH tests, as the first-line approach-a procedure that could be implemented as part of a common strategy among the scientific community to decrease current LT4 overuse.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Colorado Thyroid Disease Prevalence Study
Canaris, G. J., Manowitz, N. R., Mayor, G., & Ridgway, E. C. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.4.526 · Cited by 2,824 · cited 1×
“In fact, even the 20–25% of people with TSH values within the reference range report one or two of the above symptoms (2,7).”
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928 · cited 1×
“…have a thyrotropin (TSH) concentration of ‡ 10 IU/mL and for those with abnormal TSH concentrations but 10 IU/mL who may complain of hypothyroid-like symptoms or display positive autoantibodies or suffer from dyslipidemia, diabetes mellitus, arterial hypertension, or cardiovascular disease (5,6).”
Garber, J. R., Cobin, R. H., Gharib, H., Hennessey, J. V., Klein, I., Mechanick, J. I., Pessah-Pollack, R., Singer, P. A., & Woeber, K. A. (2012) · Endocrine Practice · doi:10.4158/ep12280.gl · Cited by 1,567
Chaker, L., Bianco, A. C., Jonklaas, J., & Peeters, R. P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30703-1 · Cited by 1,159
2013 ETA Guideline: Management of Subclinical Hypothyroidism
Pearce, S. H. S., Brabant, G., Duntas, L. H., Monzani, F., Peeters, R. P., Razvi, S., & Wemeau, J.-L. (2013) · European Thyroid Journal · doi:10.1159/000356507 · Cited by 877 · cited 1×
“Lastly, it should be mentioned that most guidelines and experts recommend that TSH values, age-adjusted for normal reference ranges, need to be confirmed twice as abnormal and that at different ages different cutoff values could be implied before LT4 is initiated (11,12).”
Self-citationFlynn, R. W., Bonellie, S. R., Jung, R. T., MacDonald, T. M., Morris, A. D., & Leese, G. P. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1625 · Cited by 415
Taylor, P. N., Iqbal, A., Minassian, C., Sayers, A., Draman, M. S., Greenwood, R., Hamilton, W., Okosieme, O., Panicker, V., Thomas, S. L., et al. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.11312 · Cited by 300 · cited 2×
“In fact, even the 20–25% of people with TSH values within the reference range report one or two of the above symptoms (2,7).”
InfluentialPitfalls in the measurement and interpretation of thyroid function tests
Koulouri, O., Moran, C., Halsall, D., Chatterjee, K., & Gurnell, M. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.10.003 · Cited by 282
Meyerovitch, J. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.14.1533 · Cited by 245 · cited 1×
“These observations are consistent with other studies showing that a high percentage of subjects with elevated TSH values revert to biochemical euthyroidism during follow-up (29–31).”
Somwaru, L. L., Arnold, A. M., Joshi, N., Fried, L. P., & Cappola, A. R. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1696 · Cited by 239 · cited 1×
“Somwaru et al . showed that among 339 LT4 users aged ‡ 65 years, only 43% were in the euthyroid range, while 41% had a low TSH (24).”
Cited by
Optimal thyroid hormone replacement
Jonklaas, J. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab031 · Cited by 89
Individualized Therapy for Hypothyroidism: Is T4 Enough for Everyone?
Ettleson, M. D., & Bianco, A. C. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa430 · Cited by 75
Thyroid function across the lifespan: do age-related changes matter?
Walsh, J. P. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.1463 · Cited by 59
“For that reason, it is recommended that subclinical hypothyroidism be confirmed by repeat testing before levothyroxine treatment is started, but in clinical practice, patients are frequently started on treatment after a single measurement of TSH [91], and many continue treatment lifelong which may be unnecessary [92]…”
BackgroundBurgos, N., Toloza, F. J. K., Singh Ospina, N. M., Brito, J. P., Salloum, R. G., Hassett, L. C., & Maraka, S. (2021) · Thyroid® · doi:10.1089/thy.2020.0679 · Cited by 53
“Four of the seven contacted authors replied (24–27).”
InfluentialFree thyroxine within the normal reference range predicts risk of atrial fibrillation
Anderson, J. L., Jacobs, V., May, H. T., Bair, T. L., Benowitz, B. A., Lappe, D. L., Muhlestein, J. B., Knowlton, K. U., & Bunch, T. J. (2020) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.14183 · Cited by 22
Prevalence and factors associated with chronic use of levothyroxine: A cohort study
Janett-Pellegri, C., Wildisen, L., Feller, M., Del Giovane, C., Moutzouri, E., Grolimund, O., Walter, P., Waeber, G., Marques-Vidal, P., Vollenweider, P., et al. (2021) · PLOS ONE · doi:10.1371/journal.pone.0261160 · Cited by 17
Willems, J. I. A., van Twist, D. J. L., Helmich, F., Sluiter, T., Medici, M., Peeters, R. P., & Tummers-de Lind van Wijngaarden, R. F. A. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf686 · Cited by 6
Metadata
- Authors
- Livadas, S., Bothou, C., Androulakis, I., Boniakos, A., Angelopoulos, N., & Duntas, L.
- Venue
- Thyroid
- Publisher
- SAGE Publications
- Published
- 2018-12
- Volume
- 28
- Issue
- 12
- Pages
- 1580-1586
- ISSN
- 1050-7256 (ISSN-L)
- 1557-9077
- OpenAlex
- W2896460854
- Cited by
- 32
- References
- 20
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.